Key result
Incretin therapies and bariatric surgery improve adiposity despite limited evidence for direct weight-independent WAT remodeling.
Why the study?
To summarize obesity-induced adaptations in subcutaneous and visceral white adipose tissue depots and discuss how incretin-based pharmacotherapies and bariatric surgery influence tissue remodeling beyond weight loss.
How do incretin-based pharmacotherapies and bariatric surgery influence white adipose tissue remodeling beyond weight loss in obesity?
How do incretin-based pharmacotherapies and bariatric surgery influence white adipose tissue remodeling beyond weight loss in obesity?
This review highlights the potential for incretin-based therapies and bariatric surgery to modulate white adipose tissue plasticity beyond simple weight loss, emphasizing the need for more longitudinal human studies.
Answers are grounded in this paper and cite their sources.
Potential adipose remodeling by incretin therapies extends preclinical insights; animal and observational data leave clinical cardiovascular implications open.
Purpose of the Review This review summarizes obesity-induced adaptations in subcutaneous and visceral white adipose tissue (WAT) depots and discusses how incretin-based pharmacotherapies and bariatric surgery may influence WAT remodeling beyond weight loss, drawing on evidence from animal models and human studies. Recent Findings In obesity, adipose tissue undergoes pathological remodeling characterized by structural and cellular changes, extracellular matrix (ECM) remodeling, altered endocrine signaling, and impaired mitochondrial function that contribute to metabolic comorbidities. Weight-loss interventions, including incretin-based therapies and bariatric surgery, are associated with improvements in adiposity and metabolic outcomes, and multiple studies suggest accompanying changes in inflammatory, mitochondrial/thermogenic, and endocrine pathways within WAT; however, mechanistic evidence in humans remains heterogeneous and is often limited by tissue accessibility and study design. Summary This review highlights candidate cellular and molecular mechanisms through which incretin-based pharmacotherapies and bariatric surgery may modulate WAT plasticity, emphasizing convergent and distinct effects across depots and the need for more longitudinal, tissue-level human studies to define weight-dependent remodeling versus changes not fully explained by weight loss.
No takes yet. Share an insight, caveat, or question.
Abud et al. (2026) conducted a review in Obesity. Incretin-based therapies and bariatric surgery was evaluated. Incretin-based therapies and bariatric surgery improve adiposity and metabolic outcomes, though evidence for direct, weight-independent remodeling of white adipose tissue in humans remains limited.
Synapse has enriched 10 related papers. Consider them for comparative context: